Summit's major focus is on developing new theraputics from its proprietary iminosugar drug discovery platform in the therapeutic areas of anti-infectives and metabolic diseases.  We believe iminosugars are the key to gaining access to several new disease mechanisms where classical drugs have had little success and offer a major opportunity for the discovery and development of new medicines.

Summit has a commercial track record of signing programme agreements and currently has an out-licensed product portfolio comprising of seven programmes.